CA
NZ
UK
AU
IND
US
…
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
CareDx is a diagnostics company focused on solid-organ transplant monitoring that offers non-invasive blood tests such as donor-derived cell-free DNA (AlloSure) and gene-expression profiling (AlloMap) together with laboratory services. Long-term growth may be supported by rising transplant volumes, wider clinical adoption of non-invasive surveillance and recurring testing revenue, and the company's specialized portfolio could appeal to investors seeking exposure to a concentrated clinical niche.
Principal risks include reimbursement and coverage uncertainty, regulatory and compliance exposure, competition from other diagnostics and laboratories, and sensitivity to transplant procedure volumes.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -21.08M | 52.86M | -190.14M | -76.23M | -32.09M |
| Net income | -21.35M | 52.55M | -190.28M | -76.61M | -30.66M |
| Selling general administrative | 107.56M | 123.78M | 117.87M | 100.40M | 74.96M |
| Selling and marketing expenses | 102.64M | 81.72M | 83.33M | 96.03M | 77.25M |
| Gross profit | 254.43M | 224.16M | 178.32M | 209.58M | 199.01M |
| Reconciled depreciation | 20.42M | 19.76M | 19.82M | 16.01M | 11.88M |
| Ebit | -21.08M | -53.75M | -104.74M | -77.23M | -29.73M |
| Ebitda | -0.67M | -33.99M | -84.92M | -77.34M | -29.83M |
| Depreciation and amortization | 20.42M | 19.76M | 19.82M | -0.11M | -0.11M |
| Non operating income net other | - | - | - | - | -2.52M |
| Operating income | -21.02M | 40.77M | -203.36M | -77.23M | -29.73M |
| Other operating expenses | 400.82M | 293.02M | 483.69M | 399.02M | 326.12M |
| Interest expense | - | - | - | 3.76M | 9.63M |
| Tax provision | 0.27M | 0.31M | 0.14M | 0.38M | -1.43M |
| Interest income | 9.17M | 11.77M | 11.87M | 3.76M | 0.16M |
| Net interest income | 9.17M | 11.77M | 11.87M | 3.76M | 0.16M |
| Income tax expense | 0.27M | 0.31M | 0.14M | 0.38M | -1.43M |
| Total revenue | 379.81M | 333.79M | 280.32M | 321.79M | 296.40M |
| Total operating expenses | 275.44M | 183.39M | 381.69M | 286.81M | 228.73M |
| Cost of revenue | 125.38M | 109.63M | 102.00M | 112.21M | 97.39M |
| Total other income expense net | -0.07M | 12.09M | 13.22M | 1.00M | -2.36M |
| Net income from continuing ops | -21.35M | 52.55M | -190.28M | -76.61M | -30.66M |
| Net income applicable to common shares | - | - | - | -76.61M | -30.66M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 413.23M | 491.05M | 484.62M | 542.99M | 566.62M |
| Intangible assets | 31.96M | 38.18M | 45.70M | 43.05M | 50.20M |
| Other current assets | 10.59M | 7.07M | 7.76M | 9.22M | 7.93M |
| Total liab | 110.13M | 112.62M | 223.29M | 112.08M | 100.75M |
| Total stockholder equity | 303.10M | 378.43M | 261.33M | 430.91M | 465.88M |
| Deferred long term liab | - | - | - | - | 0.41M |
| Other current liab | 79.86M | 70.73M | 54.51M | 55.10M | 4.73M |
| Common stock | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| Capital stock | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| Retained earnings | -735.36M | -626.24M | -678.27M | -460.44M | -383.19M |
| Other liab | - | - | - | 2.70M | 6.05M |
| Good will | 40.34M | 40.34M | 40.34M | 37.52M | 36.98M |
| Other assets | - | - | - | 4.35M | 6.05M |
| Cash | 65.43M | 114.69M | 82.20M | 89.92M | 348.49M |
| Total current liabilities | 89.85M | 89.37M | 78.07M | 75.97M | 77.30M |
| Current deferred revenue | - | 4.85M | 4.75M | 5.34M | 55.28M |
| Net debt | -45.75M | -86.32M | -47.98M | -50.92M | -331.09M |
| Short term debt | - | 6.10M | 5.94M | 5.59M | 3.96M |
| Short long term debt total | 19.68M | 28.37M | 34.22M | 39.00M | 17.39M |
| Other stockholder equity | 1043.92M | 1013.19M | 946.51M | 898.81M | 853.68M |
| Property plant equipment | - | - | - | 70.22M | 40.04M |
| Total current assets | 257.13M | 351.83M | 313.71M | 387.85M | 433.36M |
| Long term investments | 24.16M | 0.00M | - | - | - |
| Net tangible assets | - | - | - | 350.34M | 378.70M |
| Short term investments | 111.78M | 145.96M | 153.22M | 203.17M | 0.00M |
| Net receivables | 42.63M | 64.61M | 51.06M | 66.31M | 59.76M |
| Inventory | 26.70M | 19.50M | 19.47M | 19.23M | 17.19M |
| Accounts payable | 9.99M | 7.69M | 12.87M | 9.94M | 13.34M |
| Accumulated other comprehensive income | -5.51M | -8.57M | -6.96M | -7.50M | -4.67M |
| Common stock total equity | - | - | - | - | 0.05M |
| Retained earnings total equity | - | - | - | - | -383.19M |
| Non currrent assets other | 28.07M | 2.81M | 1.35M | 4.35M | 6.05M |
| Non current assets total | 156.10M | 139.22M | 170.90M | 155.14M | 133.26M |
| Capital lease obligations | 26.19M | 28.37M | 34.22M | 39.00M | 21.35M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 8.75M | -0.48M | 40.45M | -228.50M | 83.41M |
| Change to liabilities | - | - | - | -2.27M | 20.00M |
| Total cashflows from investing activities | 2.16M | -0.48M | 40.45M | -228.50M | 47.71M |
| Net borrowings | - | - | 0.00M | - | -0.07M |
| Total cash from financing activities | -93.39M | -5.61M | -29.61M | -4.54M | 185.64M |
| Change to operating activities | - | - | - | -2.43M | 10.46M |
| Net income | -21.35M | 52.55M | -190.28M | -76.61M | -30.66M |
| Change in cash | -49.29M | 32.49M | -7.66M | -258.25M | 213.76M |
| Begin period cash flow | 115.27M | 82.78M | 90.44M | 348.70M | 134.94M |
| End period cash flow | 65.98M | 115.27M | 82.78M | 90.44M | 348.70M |
| Total cash from operating activities | 42.03M | 38.05M | -18.39M | -25.24M | -19.29M |
| Issuance of capital stock | - | - | 0.00M | 0.00M | 188.85M |
| Depreciation | 20.42M | 19.76M | 19.82M | 16.01M | 11.88M |
| Other cashflows from investing activities | -6.59M | -7.12M | 1.50M | - | -35.69M |
| Dividends paid | - | - | - | - | -2.14M |
| Change to inventory | -4.96M | -1.02M | 0.05M | -2.86M | -6.93M |
| Change to account receivables | 22.52M | -13.74M | 16.02M | -6.66M | -24.42M |
| Sale purchase of stock | -87.77M | -0.52M | -27.54M | -0.64M | 2.14M |
| Other cashflows from financing activities | -13.62M | -5.08M | -2.06M | -6.33M | -3.15M |
| Change to netincome | - | - | - | 49.58M | 37.95M |
| Capital expenditures | 5.91M | 6.48M | 9.24M | 24.33M | 20.26M |
| Change receivables | - | - | - | - | -24.42M |
| Cash flows other operating | - | - | - | - | -25.16M |
| Cash and cash equivalents changes | - | - | - | - | 214.06M |
| Change in working capital | 3.81M | -102.31M | 106.03M | -14.22M | -40.97M |
| Stock based compensation | 34.86M | 66.41M | 49.09M | 46.55M | 36.08M |
| Other non cash items | 4.28M | 1.83M | -3.61M | 3.25M | 0.30M |
| Free cash flow | 36.12M | 31.56M | -27.63M | -49.57M | -39.55M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CDNA CareDx Inc |
15.89 22.22% |
87.41 | - | 97.09 | 2.81 | 3.60 | 2.48 | 65.47 |
| TMO Thermo Fisher Scientific Inc |
-12.18 1.72% |
697.00 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-4.75 2.00% |
232.23 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.25 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.73 3.01% |
23.56 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. Reginald Seeto | Pres, CEO & Director | 1972 |
| Dr. Peter Maag Ph.D. | Exec. Director | 1967 |
| Ms. Sasha King M.B.A. | Exec. Officer | 1986 |
| Mr. Marcel Konrad | Sr. VP of Fin. & Accounting | 1976 |
| Mr. Alexander L. Johnson | Pres of Patient and Testing Services | 1974 |
| Mr. Abhishek Jain | CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer | 1976 |
| Ms. Marica Grskovic Ph.D. | Chief Operating Officer | NA |
| Mr. Abraham Ronai Esq. | Gen. Counsel, Chief Admin. & Legal Officer and Sec. | 1973 |
| Mr. Ian Cooney | VP of Investor Relations | NA |
| Dr. Mickey Y. Kim M.D. | Sr. VP of Corp. Devel. & Head of Global Product | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...